Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × INDUSTRY × Macular Degeneration × Clear all

Phase

Status

Terminated 1 Recruiting 1 Enrolling by invitation 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 430 Carcinoma, Non-Small-Cell Lung 387 Breast Neoplasms 305 Neoplasm Metastasis 212 Colorectal Neoplasms 184 Melanoma 183 Leukemia, Myeloid, Acute 171 Multiple Myeloma 156 Ovarian Neoplasms 150 Prostatic Neoplasms 149 Recurrence 146 Lymphoma, Non-Hodgkin 130 Lung Neoplasms 111 Lymphoma 107 Pancreatic Neoplasms 103 Carcinoma, Renal Cell 100 Leukemia, Lymphocytic, Chronic, B-Cell 97 Squamous Cell Carcinoma of Head and Neck 95 Stomach Neoplasms 79 Carcinoma, Hepatocellular 79 Leukemia 78 Lymphoma, Large B-Cell, Diffuse 74 Lymphoma, Follicular 74 Triple Negative Breast Neoplasms 72 Head and Neck Neoplasms 68 Glioblastoma 65 Myelodysplastic Syndromes 62 Urinary Bladder Neoplasms 61 Small Cell Lung Carcinoma 52 Brain Neoplasms 46

Interventions

brolucizumab 1 aflibercept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡